Siegfried Announces Changes in Senior Management Team

Siegfried has appointed Marianne Späne, currently chief business officer Drug Products, as chief business officer with responsibility for both the Drug Substances and Drug Products divisions of the Swiss contract manufacturing and development organization (CDMO), effective Feb. 1, 2024. Christian Dowdeswell, who previously led the Drug Substance business, has decided to leave Siegfried.

Siegfried also announced the following personnel changes: Klaus Stingl, currently head of the company’s Zofingen site, has been appointed as global head of Business Development and Sales Drug Substances, effective Feb. 1, 2024. Martin Kessler, formerly chief transformation officer at Rentschler, will become CEO of Dinamiqs, a Siegfried subsidiary, as of Mar. 1, 2024, while the current CEO Eduard Ayuso will become chief technology officer.

Manja Boerman, formerly president Cell, Gene and Protein Therapy at Catalent, is to join as a new independent board member of Dinamiqs.

In his new role, Stingl becomes member of Siegfried’s extended executive committee. He joined the company in 2016. Prior to Siegfried, Stingl held several senior positions at Evonik. He holds a Ph.D. in organic chemistry from University of Oldenburg, Germany.

© Siegfried AG
© Siegfried AG

Company

Siegfried

Untere Brühlstr. 4
4800 Zofingen
Switzerland

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis